AGT and cardiomyopathy: Xirp2 has been shown to be upregulated in some cardiomyopathies (Jung-Ching Lin et al., 2005; Duka et al., 2006; Wang et al., 2014) and mice engineered to express reduced levels of Xirp2 are partly protected from angiotensin-II-induced cardiomyopathic remodeling (McCalmon et al., 2010).